Table 3 The median values of the haematological parameters of the 39 C1-INH-HAE patients taking danazol before treatment as well as after 1-, 3-, and 5-year treatment with danazol
From: The effect of long-term danazol treatment on haematological parameters in hereditary angioedema
Parameter | Gender | Reference range | Median before 1-year treatment | Median after 1-year treatment | Median before 3-year treatment | Median after 3-year treatment | Median before 5-year treatment | Median after 5-year treatment |
|---|---|---|---|---|---|---|---|---|
WBC | Males | 4.0–10.0 × 109/L | 8.54 (5.83–10.5) | 6.76 (5.70–9.06) | 7.90 (5.83–10.0) | 6.57 (5.40–8.63) | 8.30 (5.83–10.10) | 7.83 (5.52–8.53) |
Females | 7.60 (6.70–10.57) | 7.80 (6.55–9.22) | 7.60 (7.03–9.88) | 7.88 (6.48–8.61) | 7.60 (6.80–10.7) | 6.45 (5.43–7.12)* | ||
RBC | Males | 4.50–5.90 × 1012/L | 5.17 (4.82–5.37) | 5.14 (4.79–5.35) | 5.21 (4.84–5.38) | 5.14 (4.70–5.29) | 5.20 (4.82–5.39) | 5.21 (4.74–5.52) |
Females | 4.10–5.10 × 1012/L | 4.60 (4.33–4.73) | 4.61 (4.31–4.81) | 4.60 (4.33–4.73) | 4.55 (4.45–4.69) | 4.62 (4.27–4.76) | 4.60 (4.32–4.67) | |
Hb | Males | 140–175 g/L | 154 (149–161) | 153 (146–160) | 154 (152–161) | 154 (144–158) | 156 (151–161) | 157 (151–162) |
Females | 123–153 g/L | 133 (124–142) | 137 (127–140) | 133 (122–141) | 135 (131–139) | 133 (124–142) | 138 (129–144) | |
Hct | Males | 0.36–0.48 L/L | 0.46 (0.43–0.48) | 0.45 (0.42–0.46) | 0.46 (0.43–0.48) | 0.45 (0.43–0.46) | 0.45 (0.43–0.48) | 0.45 (0.44–0.48) |
Females | 0.35–0.45 L/L | 0.39 (0.38–0.42) | 0.42 (0.38–0.42) | 0.39 (0.38–0.42) | 0.40 (0.39–0.41) | 0.39 (0.38–0.42) | 0.41 (0.38–0.43) | |
PLT | Males | 150–400 × 109/L | 270 (232–300) | 254 (230–315) | 270 (231–314) | 258 (227–333) | 263 (230–322) | 241 (222–285) |
Females | 291 (246–329) | 265 (248–323) | 302 (250–346) | 286 (253–313) | 302 (257–336) | 262 (218–297)* |